Polaryx Therapeutics (NASDAQ:PLYX) Stock Price Down 1.9% - Time to Sell?

Key Points

• Shares fell 1.9% mid-day to $5.54 (intraday low $5.11) on volume of 1,158,292 shares, a 63% decline versus the average session volume of 3,144,816.
• Maxim Group initiated coverage with a Buy rating and a $10 target (MarketBeat shows an average rating of Buy and a $10 average target, based on one analyst).
• Polaryx is a clinical-stage biotechnology developing multi-modal treatments — including small molecules, combination therapies and gene therapy — for rare pediatric lysosomal storage disorders.

Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) shares fell 1.9% during mid-day trading on Friday . The company traded as low as $5.11 and last traded at $5.54. 1,158,292 shares were traded during trading, a decline of 63% from the average session volume of 3,144,816 shares. The stock had previously closed at $5.65.

Analyst Upgrades and Downgrades

Separately, Maxim Group started coverage on shares of Polaryx Therapeutics in a research note on Friday, February 27th. They issued a "buy" rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Polaryx Therapeutics presently has an average rating of "Buy" and an average target price of $10.00.

Polaryx Therapeutics Trading Down 1.9%

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.